- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06495996
Studien Protrieve PROTECTOR (PROTECTOR)
PROTECTOR: Utvärdering av säkerheten och effektiviteten hos Protrieve Sheathen för att förhindra kliniskt signifikant intraprocedurell lungemboli genom att tillhandahålla emboliskt skydd i IVC under trombektomiprocedurer för att behandla DVT
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection in the IVC during thrombectomy procedures to treat DVT.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
California
-
Newport Beach, California, Förenta staterna, 92663
- Hoag Hospital
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06510
- Yale University
-
-
Florida
-
Miami, Florida, Förenta staterna, 33176
- Baptist Health South Florida
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46204
- IU Health Methodist Hospital
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21218
- MedStar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Beth Israel Deaconess Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89102
- University Medical Center Southern Nevada
-
-
New Jersey
-
Englewood, New Jersey, Förenta staterna, 07631
- Englewood Hospital
-
-
New York
-
New York, New York, Förenta staterna, 10016
- NYU Langone Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15212
- Allegheny General Hospital
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Vanderbilt University Medical Center
-
-
Texas
-
Galveston, Texas, Förenta staterna, 77555
- University of Texas Medical Branch
-
Houston, Texas, Förenta staterna, 77030
- University of Texas MD Anderson Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26506
- West Virginia University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Age ≥ 18 years
-
Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
- Bilateral iliofemoral DVT
- Clot extending into or located in the IVC
- In-stent thrombosis
- Presence of thrombosed IVC filter
- Other features that the investigator deems put the subject at elevated risk for thromboembolism
-
Willing and able to provide informed consent
Exclusion Criteria:
- Current symptomatic PE
- Known anatomic inability to place Protrieve device via jugular vein access site
- Presence of clot extending to the IVC-Right Atrial junction or in the SVC
- Subject is pregnant
- Severe allergy to iodinated contrast agents that cannot be mitigated
- INR > 1.7 if not currently on anticoagulation therapy, platelets < 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin < 8.0 g/dL
- Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
- Subject is participating in another study that may interfere with this study
- Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Subject has previously completed or withdrawn from this study
- Limb-threatening circulatory compromise (e.g., phlegmasia)
- Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
- Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
- Inability to provide therapeutic anticoagulation per Investigator discretion
- Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Protrieve Sheath
The Protrieve Sheath is intended for embolic protection in the inferior vena cava (IVC) to prevent clinically significant intraprocedural pulmonary embolism during mechanical thrombectomy procedures in patients with high risk of embolization. |
Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Primary Effectiveness Measure:
Tidsram: 24 Hours (+-12 Hours)
|
a. Clinically significant PE |
24 Hours (+-12 Hours)
|
|
Primary Safety Measure:
Tidsram: 24 Hours (+-12 Hours)
|
|
24 Hours (+-12 Hours)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Capture of Thromboembolic Material
Tidsram: 24 Hours (+-12 Hours)
|
a. Capture and removal of thromboembolic material in the Protrieve funnel, as assessed by proportion of study cases where any material was either entrapped in the funnel or removed via Protrieve |
24 Hours (+-12 Hours)
|
|
Device Success
Tidsram: 24 Hours (+-12 Hours)
|
b. Device success, defined as successful delivery, deployment, and retrieval of the Protrieve device without complications |
24 Hours (+-12 Hours)
|
|
Venous Access Routes
Tidsram: 24 Hours (+-12 Hours)
|
c. Thrombectomy via supplementary venous access routes |
24 Hours (+-12 Hours)
|
|
Estimated Percentage of the Protrieve Funnel Obstructed
Tidsram: 24 Hours (+-12 Hours)
|
d. Estimated percentage of the Protrieve funnel obstructed by clot, as observed by visual inspection or imaging |
24 Hours (+-12 Hours)
|
|
Blood Transfusions
Tidsram: 24 Hours (+-12 Hours)
|
e. Blood transfusions associated with Protrieve Sheath access site bleeding |
24 Hours (+-12 Hours)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Ripal Gandhi, MD, Baptist Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 23-003
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .